Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:42:21 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:RNAZ from 2023-04-27 to 2024-04-26 - 39 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-15 09:00U:RNAZNews ReleaseTransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
2024-04-03 09:10U:RNAZNews ReleaseTransCode Therapeutics Reports 2023 Results; Provides Business Update
2024-03-28 08:30U:RNAZNews ReleaseTransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
2024-03-11 09:00U:RNAZNews ReleaseTransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
2024-03-06 16:15U:RNAZNews ReleaseTransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
2024-02-20 08:00U:RNAZNews ReleaseTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode ¢ € ™s RIG-I Agonist Immunotherapeutic
2024-01-31 16:05U:RNAZNews ReleaseNasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders ¢ € ™ Equity Requirement and Continued Listing on The Nasdaq Stock Market
2024-01-29 08:30U:RNAZNews ReleaseTransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
2024-01-22 16:45U:RNAZNews ReleaseTransCode Therapeutics Announces Closing of $7.25 Million Public Offering
2024-01-18 13:28U:RNAZNews ReleaseTransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
2024-01-12 16:05U:RNAZNews ReleaseTransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
2024-01-11 08:00U:RNAZNews ReleaseTransCode Therapeutics Announces 1-for-40 Reverse Stock Split
2024-01-04 08:05U:RNAZNews ReleaseTransCode Therapeutics Publishes Open Letter Outlining Company ¢ € ™s Progress and Objectives
2023-12-12 08:30U:RNAZNews ReleaseTransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
2023-12-05 09:00U:RNAZNews ReleaseTransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
2023-12-04 16:10U:RNAZNews ReleaseTransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
2023-11-30 14:53U:RNAZNews ReleaseTransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
2023-11-14 16:30U:RNAZNews ReleaseTransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
2023-10-30 16:34U:RNAZNews ReleaseTransCode Therapeutics Withdraws Public Offering
2023-10-27 08:00U:RNAZNews ReleaseNasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
2023-10-26 16:19U:RNAZNews ReleaseTransCode Therapeutics Announces ‚  Public Offering of Common Stock
2023-10-26 08:00U:RNAZNews ReleaseTransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
2023-10-24 08:00U:RNAZNews ReleaseTransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
2023-10-16 08:00U:RNAZNews ReleaseTransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA
2023-09-28 16:02U:RNAZNews ReleaseTransCode Therapeutics Announces Closing of $8.5 Million Public Offering
2023-09-25 20:01U:RNAZNews ReleaseTransCode Therapeutics Announces Pricing of $8 Million Public Offering
2023-09-25 08:30U:RNAZNews ReleaseTransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
2023-08-23 08:00U:RNAZNews ReleaseTransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
2023-08-14 16:45U:RNAZNews ReleaseTransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
2023-07-31 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
2023-07-13 12:44U:RNAZNews ReleaseStonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi
2023-07-05 07:00U:RNAZNews ReleaseTransCode Therapeutics CEO Letter to Shareholders
2023-06-28 15:50U:RNAZNews ReleaseTransCode Therapeutics making preclinical progress with lead metastatic cancer candidate
2023-06-22 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
2023-06-09 16:05U:RNAZNews ReleaseTransCode Therapeutics Announces Closing of $7 Million Public Offering
2023-06-06 17:30U:RNAZNews ReleaseTransCode Therapeutics Announces Pricing of $7 Million Public Offering
2023-06-06 16:01U:RNAZNews ReleaseTransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
2023-05-22 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces 1-for-20 Reverse Stock Split
2023-04-27 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial